iCo-008 is a type of antibody—called a monoclonal antibody—designed to target a protein called eotaxin-1, which triggers inflammatory allergic reactions such as those found with some ocular diseases, severe asthma and inflammatory bowel disease. Monoclonal antibodies have the unique ability to bind to almost any substance, including disease organisms in the human body. Through this targeting and binding process, iCo-008 blocks eotaxin-1, neutralizing its ability to deliver the signal that triggers allergic reaction. iCo-008 can be administered intravenously, intra-nasally, or topically (the eye).

POTENTIAL INDICATIONS

Ocular Markets
- Vernal and Atopic Keratoconjunctivitis

Systemic Markets (license granted to Immune Pharmaceuticals)
- Inflammatory Bowel Disease, Crohn’s disease
- Severe Asthma
- Bullous Pemphigoid
- Ulcerative Colitis

PRODUCT HIGHLIGHTS
- Human monoclonal antibody targeting eotaxin-1
- Good safety & significant clinical history: Phase 1 & 2 (n=126)
- iCo-008 utilizes a targeted, highly specific biological approach
- Eotaxin binds with high affinity to CCR3

CLINICAL HISTORY

Phase 1: (n=25) No serious adverse events
Phase 2: (n=101) Applied intranasally & topically to the eye
- Safe and well tolerated
- Evidence of efficacy in severe allergy indication: reduced post allergy nasal obstruction

RECENT & UPCOMING MILESTONES
- License systemic rights to Immune Pharmaceuticals for US$32+ million while retaining ocular rights
- Pursuing non-dilutive funding for ocular programs
- Immune data for Bullous Pemphigoid, 2015
- Immune data for Ulcerative Colitis, 2016